Sibutramine in the treatment of obesity in women

Sadikova Nigora Gayratovna, Nazhmutdinova Diloram Kamariddinovna, Urunbaeva Diloram Anvarovna, Inoyatova Iroda Shakirovna

dc.contributor.author	Sadikova Nigora Gayratovna, Nazhmutdinova Diloram Kamariddinovna, Urunbaeva Diloram Anvarovna, Inoyatova Iroda Shakirovna
dc.date.accessioned	2020-03-03T06:45:21Z
dc.date.available	2020-03-03T06:45:21Z
dc.date.issued	2019
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/489
dc.description.abstract	We studied 30 obese women aged 43.5±3.2 years. All patients, depending on the received therapy, were divided into two groups: 1 group consisted of 15 patients receiving sibutramine, 2 group consisted of women receiving sibutramine and Metformin. All women were measured weight, height, then calculated body mass index, waist (W) and hip (H), also fasting blood sugar and 2 hours after eating, lipid spectrum, to eliminate hypothyroidism hormones TSH, free T3, free T4, antibodies to TPO. During the treatment of sibutramine with Metformin in combination led to a decrease in body weight in 15% of patients, sibutramine monotherapy was observed in 10%.	en_US
dc.language.iso	other	en_US
dc.publisher	Tashkent	en_US
dc.subject	Keywords: obesity, body mass index, sibutramine, total cholesterol, triglycerides	en_US
dc.title	Sibutramine in the treatment of obesity in women	en_US
dc.type	Article	en_US